Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.25, $0.01 better than the analyst estimate of $0.24. Revenue for the quarter came in at $59.3 million versus the consensus estimate of $59.05 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.